CagriSema Phase 3 Trial Achieves Primary Endpoint with Record Weight Loss
Novo Nordisk's CagriSema combination therapy hits primary endpoint in phase 3 trial, demonstrating weight loss exceeding 25% and positioning the company for regulatory submission.
Novo Nordisk announced positive top-line results from the REDEFINE 2 phase 3 trial evaluating CagriSema, the company’s combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). The trial met its primary endpoint, with participants achieving mean weight loss of approximately 25.3% from baseline, representing the highest efficacy demonstrated in any obesity drug pivotal trial to date.
What We Know
The REDEFINE 2 trial enrolled approximately 3,400 adults with obesity without type 2 diabetes, randomizing participants to receive weekly subcutaneous CagriSema, semaglutide 2.4mg alone, or placebo. The 68-week treatment period evaluated weight loss as the primary endpoint, with secondary endpoints including cardiometabolic parameters and quality of life measures [redefine-2-trial].
Participants receiving CagriSema achieved mean weight loss of 25.3%, compared to approximately 16.8% with semaglutide alone and 2.1% with placebo [novo-cagrisema-2025]. The superiority of CagriSema over semaglutide monotherapy reached statistical significance, demonstrating the additive benefit of the dual-mechanism approach.
The safety profile was consistent with previous trials and the known effects of both component medications. Gastrointestinal adverse events including nausea, vomiting, and diarrhea were the most commonly reported side effects, occurring at slightly higher rates than with semaglutide alone but generally decreasing over time with continued treatment.
The Science Behind CagriSema
CagriSema combines two distinct mechanisms targeting appetite and metabolism. Semaglutide, already established as an effective obesity treatment, activates GLP-1 receptors in the brain and pancreas, reducing appetite and improving glucose metabolism.
Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells. Amylin contributes to satiety through effects on the area postrema in the brainstem and slows gastric emptying, complementing GLP-1’s effects [amylin-research].
The combination appears to produce synergistic effects on appetite reduction and energy balance that exceed what either component achieves alone. This aligns with the emerging understanding that obesity involves multiple regulatory pathways, and targeting multiple mechanisms may be necessary for optimal outcomes.
What It Means
The REDEFINE 2 results position CagriSema as a potentially best-in-class obesity treatment, at least among injectable options currently in late-stage development. The approximately 8.5 percentage point improvement over semaglutide alone represents a clinically meaningful difference that could influence treatment selection.
For Novo Nordisk, the results strengthen the company’s competitive position against Eli Lilly’s retatrutide and other emerging therapies. Having both the current market-leading semaglutide products and a next-generation combination therapy provides strategic flexibility.
The implications for patients are significant. Weight loss exceeding 25% approaches outcomes historically achieved only through bariatric surgery. For individuals with severe obesity and related comorbidities, medications achieving this level of efficacy could provide meaningful alternatives to surgical intervention.
However, access and cost questions persist. CagriSema will likely carry a premium price over semaglutide alone, and insurance coverage for obesity medications remains inconsistent. The clinical benefits demonstrated in trials must ultimately reach patients who can afford and access treatment.
What’s Next
Novo Nordisk indicated plans to submit regulatory applications to the FDA and European Medicines Agency in early 2026, targeting potential approval in late 2026 or early 2027.
Additional trials in the REDEFINE program are ongoing, including studies in patients with type 2 diabetes and those examining cardiovascular outcomes. These studies will further define CagriSema’s therapeutic profile and potential indications.
Manufacturing preparations are underway to support commercial launch. Given the supply constraints that have affected semaglutide products, ensuring adequate production capacity will be critical for successful market entry.
The obesity treatment landscape continues to evolve rapidly. Within the next two to three years, healthcare providers and patients may have multiple options achieving weight loss exceeding 20%, fundamentally changing the approach to obesity management.
This information is provided for educational purposes only and does not constitute medical advice. Patients considering any medication should consult with qualified healthcare providers to discuss their individual circumstances.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.